Key secondary endpoints include response rates at the end of treatment, time to response ... ASyS is characterized by muscle inflammation, inflammatory arthritis, interstitial lung disease, thickening ...
Icotrokinra, formerly known as JNJ-2113, is an investigational oral peptide that blocks the interleukin (IL)-23 receptor, which plays a significant role in the pathogenesis of moderate to severe ...